VolitionRx Statistics
Total Valuation
VolitionRx has a market cap or net worth of $65.10 million. The enterprise value is $73.78 million.
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VolitionRx has 107.60 million shares outstanding. The number of shares has increased by 18.11% in one year.
| Current Share Class | 107.60M |
| Shares Outstanding | 107.60M |
| Shares Change (YoY) | +18.11% |
| Shares Change (QoQ) | +6.34% |
| Owned by Insiders (%) | 7.91% |
| Owned by Institutions (%) | 14.76% |
| Float | 77.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.65 |
| Forward PS | 5.04 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 55.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.35
| Current Ratio | 0.35 |
| Quick Ratio | 0.26 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.27 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -134.74% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 4,377.87% |
| Revenue Per Employee | $15,521 |
| Profits Per Employee | -$274,385 |
| Employee Count | 85 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.94% in the last 52 weeks. The beta is 1.27, so VolitionRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -1.94% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.61 |
| Relative Strength Index (RSI) | 43.72 |
| Average Volume (20 Days) | 199,653 |
Short Selling Information
The latest short interest is 313,967, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 313,967 |
| Short Previous Month | 177,966 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.41% |
| Short Ratio (days to cover) | 1.31 |
Income Statement
In the last 12 months, VolitionRx had revenue of $1.32 million and -$23.32 million in losses. Loss per share was -$0.25.
| Revenue | 1.32M |
| Gross Profit | 1.32M |
| Operating Income | -23.47M |
| Pretax Income | -23.52M |
| Net Income | -23.32M |
| EBITDA | -22.38M |
| EBIT | -23.47M |
| Loss Per Share | -$0.25 |
Full Income StatementBalance Sheet
The company has $2.26 million in cash and $10.94 million in debt, giving a net cash position of -$8.69 million or -$0.08 per share.
| Cash & Cash Equivalents | 2.26M |
| Total Debt | 10.94M |
| Net Cash | -8.69M |
| Net Cash Per Share | -$0.08 |
| Equity (Book Value) | -33.10M |
| Book Value Per Share | -0.31 |
| Working Capital | -5.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.38 million and capital expenditures -$287,929, giving a free cash flow of -$21.67 million.
| Operating Cash Flow | -21.38M |
| Capital Expenditures | -287,929 |
| Free Cash Flow | -21.67M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,778.98% |
| Pretax Margin | -1,782.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VolitionRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.11% |
| Shareholder Yield | -18.11% |
| Earnings Yield | -35.83% |
| FCF Yield | -33.29% |
Analyst Forecast
The average price target for VolitionRx is $3.50, which is 478.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 478.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 166.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
VolitionRx has an Altman Z-Score of -47.54 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -47.54 |
| Piotroski F-Score | 3 |